Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum...
MORRISTOWN, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Orexo (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space...
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today...
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at...
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry...
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry...
TORONTO, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Kerr Mines Inc. (TSX:KER) (OTC:KERMF) (FRA:7AZ1) (“Kerr” or the “Company”) is pleased to announce that the Company has divested all of its interest in...
Regulatory News: Orexo AB (publ.) (STO:ORX) announces that the United States District Court for the District of Delaware ruled in Orexo’s favor in one of the patent infringement...
The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs and, as previous announced, by issue...
Regulatory News: Orexo (STO:ORX) Strong Zubsolv® and Abstral® revenue growth. Third quarter 2016 · Total net revenues MSEK 181.9 (139.5). · Zubsolv net revenue MSEK...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
